Regulatory & Legal

A new $4.2 billion coastal city in Muscat aims to merge luxury living with a digital economy. Can Oman's 'MAD' project redefine real estate and its future?

Sensorion clears a key safety hurdle for its infant hearing loss gene therapy, but early data reveals a tight race to market against formidable rivals.

New 52-week data shows Protagonist and Takeda's drug slashes phlebotomy needs, signaling a major shift in quality of life for polycythemia vera patients.

A medical breakthrough dismantles a core barrier in cancer treatment, making stem cell transplants a reality for nearly everyone, regardless of ancestry.

A junior miner's auditor and finance chief changes signal a calculated move to de-risk its path to becoming a major developer of a 'green' gold mine.

USA Pickleball's exclusive DUPR deal aims to unify the sport, but a single rating system brings both professional legitimacy and player controversy.

A seizure of fake Viagra at a Toronto convenience store reveals the dangerous shadow economy of counterfeit drugs threatening public health and business integrity.

Following a strategic merger, the National Down Syndrome Society appoints six new leaders, signaling a new era of inclusive, research-driven advocacy.

Boston-based 1910 Genetics unveils an AI model that bypasses decades-old barriers, opening a vast new frontier for treating Alzheimer's and Parkinson's.

Healthcare tech firm StaffDNA’s title sponsorship of the Cure Bowl is more than a game—it's a calculated move blending branding with a cancer research mission.

A legal fight over attorney fees in the Hess-Chevron deal reveals a costly risk in M&A. Here's why healthcare execs and investors should pay attention.

BlackRock has once again boosted its holding in Finnish drugmaker Orion to over 5%. We decode what this calculated move signals for Orion's future.

New long-term data suggests zorevunersen may modify Dravet syndrome, not just treat it. A look at the science, the strategy, and the stakes.

New data on RAP-219 reveals more than just seizure control; it shows a strategic play to redefine treatment and capture the neurology market.

A routine filing from a quant fund reveals subtle shifts in the high-stakes merger of American Axle and Dowlais. What does it mean for the bottom line?

Intensity Therapeutics has a promising cancer therapy in late-stage trials, but can its scientific innovation outpace a looming Nasdaq delisting threat?

Abaxx is launching UK wind futures, a critical financial tool to manage renewable energy volatility. Is this the key to de-risking the energy transition?

A key regulatory filing reveals growing investor confidence in the American Axle-Dowlais deal, a move poised to reshape the global automotive supply chain.

A shareholder lawsuit challenges Comerica's $10.9B sale to Fifth Third, citing a rushed process, CEO self-interest, and an undervalued price.

Beyond straight teeth, a new aligner offers non-surgical jaw correction for adults, shaking up a multi-billion dollar market. Is this the future?